DXRX
The Diagnostic Network

by
Diaceutics

Collaboration Opportunity: Investigation if a uniform and separate code for PD-L1 testing is required | US

PD-L1 precision medicine has rapidly expanded in the last few years however, a shift toward send out testing has been observed as laboratories are unable to justify the associated costs for providing this service due to testing being insufficiently reimbursed.

Availability of only the general IHC CPT codes; which result in limited reimbursement for an analyte that is selective for therapy, conflicts with the requirement for the use of a variety of FDA-approved companion diagnostic (CDx) kits that have been specifically matched for different indications, assay cut-points and interpretation procedures.

The question at hand is if test affordability may result in the incorrect test being performed and the patient receiving a result that is incorrectly matched to the therapy being considered.

Why join the collaboration:

- Be a thought leader and help build a repository of evidence that will allow a consortium of partners to pursue an improved reimbursement model for PD-L1 testing
- Join a network of laboratory and pharma stakeholders who want to engage the AMA and CMS in designating a specific and separate code for the technical component of PD-L1 IHC testing
- Help establish a more equitable level of reimbursement for PD-L1 companion diagnostic testing, which could support laboratories' ability to perform the proper testing aligned to national recommendations and therapy labels and result in improved patient outcomes

Additional information

To be eligible to participate in this collaboration please ensure that:

- Lab profile information reflects:
  - Available in-house IHC auto-stainer details
  - External Quality Assurance (EQA) schemes or proficiency testing (PT) programs that are being subscribed to for PD-L1 testing
- Your lab assay details reflect:
  - Current PD-L1 testing methods and turnaround times
  - Scoring algorithms and reporting formats

*Please note, where multiple assays are available in-house, these have to be logged as individual assays per antibody

Collaboration process



Discover DXRX Collaborations